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Literature Review & Rationale
In the United States alone, approximately 1 in 8 women will develop invasive breast
cancer in her lifetime making breast cancer the second most common and second most lethal
cancer amongst women. According to American Cancer Society, 246,660 new cases of breast
cancer will be diagnosed this year in 20161. Not only is a breast cancer patient affected
physically, but they will also be affected emotionally and psychologically. The effects are
experienced by the family, friends, and colleagues and can cause shock, sadness, anxiety, and
even anger2.
There are many risk factors which can increase a woman’s likelihood of developing
breast cancer. Unfortunately, many of these factors are uncontrollable such as: being female,
increased age, genetic factors, and family history. However, there are many factors that are
controllable such as: exercise, weight, various environmental factors, and diet1.
The metastases of breast cancer are among one of the highest rates compared to other
cancers and leads to a higher rate of mortality3. Metastasis is the development of secondary
malignant growth that in sites distal from the primary tumor. It has been estimated that about 2030% of breast cancer cases lead to metastasis4 and an estimated 40,450 women will die from
breast cancer in 20161. There are many different sites in the body where it can metastasize; each
different site will have different behaviors and severity3. The most common sites of breast
cancer metastasis is lungs, brain, liver, and bone. The variations in behavior and severity of
metastasis support the seed and soil hypothesis. The seed and soil hypothesis explains that a
primary tumor may metastasize (the seed) and begin growing at a distal site (the soil). These
distant sites display differential characteristics in gene expression, growth factors, and receptors3.

Over the years, evidence has emerged suggesting vitamin D may reduce the risk of breast
cancer although the relationship is not fully understood. Evidence shows that lower vitamin D is
associated with an increased risk of metastasis, but the mechanistic basis for this is not well
known. Studies have additionally identified an inverse association between serum 25
hydroxyvitamin D (25(OH)D) levels, a marker for vitamin D status, and the risk of breast
cancer9. The active form of vitamin D, 1,25dihydroxyvitamin D (1,25 (OH)2D) has been shown
to regulate a variety of components of cancer progression, including inhibiting cell proliferation
and cell cycle arrest, as well as promoting cell differentiation and apoptosis in breast cancer cells
in numerous studies10,11.
There are two primary forms of vitamin D obtainable from the environment.
Cholecalciferol, or vitamin D3, is produced from cholesterol in the skin when exposed to sunlight
or ultraviolet light. Ergocalciferol, or vitamin D2, is obtained from the diet. Vitamin D3 is
hydroxylated in the liver to form its dominant circulating, inactive form, 25(OH)D6. This
inactive form 25(OH)D is converted to its active form1,25(OH)2D by the enzyme 25hydroxyvitamin D1α-hydroxylase. This process occurs in the proximal tubules of the kidney as
well as in many other tissues including: immune system, skin, adrenal medulla, pancreatic islet
cells, colon, and breast7. The active form, 1,25(OH)2D, is a secosteroid that is known for its role
in regulating calcium and phosphate homeostasis in part through parathyroid hormone secretion
via stimulating absorption from the gut, increasing calcium absorption and renal reabsorption 6.
There are a range of other cellular functions associated with 1,25(OH)2D including:
antiproliferation, immunomodulatory properties, disease prevention5, differentiation, and many
others6. The nuclear vitamin D receptor (VDR) binds to 1,25(OH)2D functioning as a
transcription factor in both normal and neoplastic cells5. VDR binds to one of the retinoid X

receptors, forming a dimer that interacts with coactivators assisting in recruiting the RNA
polymerase II complex. These coactivators are responsible for activating various gene
expression8. Figure 1 represents the metabolism of vitamin D.

Figure 1. Vitamin D Metabolism.
The metabolism of vitamin D3 into
its active form,
1,25dihydroxyvitamin D3
(1,25(OH)2D3) requires several steps.
The active form functions as a
hormone and transcription factor to
its receptor vitamin D receptor
(VDR). VDR forms a dimer with
retinoid X receptor (RXR) and
functions to recruit the RNA
polymerase II transcription complex8.

In breast cancer cells, regulation of the cell cycle is transformed12. Previous findings
from our lab have shown an association between 1,25(OH)2D treatment with decreased viable
cell number, induction of cell apoptosis, and cell cycle regulation by inducing G1/G0 cell cycle
arrest. These results were modeled using MFC10A cells transfected with the Harvey ras
oncogene (MCF10A-ras). This inhibition of cell cycle proliferation could contribute to the
decrease in viable cell number via 1,25(OH)2D and therefore preventing breast cancer
progression and cell cycle regulation.
The cell cycle is composed of a series of events that control the replication of the genetic
material and division of the cell13. The process is tightly controlled and divided into phases12. G0

is a separate state in which cells are in a quiescent state. During proliferation the cell transitions
through G1, a gap phase in which the cell increases in size as it grows and synthesizes mRNA
and proteins. The cell then moves into the S phase, in which precise DNA replication occurs in
the nucleus. Next, the cell enters another gap phase, G2, as the cell continues to grow. Finally,
the cell will enter M phase, where mitosis occurs and the cell divides via cytokinesis13. Figure 1
shows a summary of the steps of the cell cycle.
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Figure 1. The phases of the cell cycle. The
cell cycle progress from G1 gap phase (growth
and protein synthesis) to S phase (synthesis) to
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G2 gap phase (growth) and finally through M
phase (mitosis via cytokinesis). 10

Throughout the cell cycle, there are various cell cycle check points that function to ensure
accurate propagation. There are numerous molecules and proteins that are utilized as regulators
of the cell cycle to ensure proper transition12. Control of the G2/M transition has been found to be
associated with cancer because it may result in chromosomal aberrations. The G1/S transition
may be altered in breast cancer cells, where oncogenes may disrupt the normal function of genes
and tumor suppressors. The arrest of cells in the G1/S phase prevents them from proliferating
and further growth which is considered an essential component of cancer cells. During cancer
development, several cell cycle regulator molecules have been found to be overexpressed,
leading to loss of normal growth regulation and increased proliferation 12. The active form of
vitamin D has been known to play a role in cell cycle arrest in breast cancer cells10, 11. It has been
found that 1,25(OH)2D effects the expression of specific cell cycle regulators which can initiate

G1/G0 cell cycle arrest and promote apoptosis14. One type of cell cycle regulator, cyclindependent kinase inhibitors (CDI’s) negatively modulate the progression of the cell cycle. One
CDI in particular, p27Kip1, interacts with CDK2 and CDK4 by inhibiting cell cycle progression at
the G1 phase when grown with 1,25(OH)2D15. Studies have shown that the addition of
1,25(OH)2D to neoplastic cells is associated with an increase in p27Kip1, suggesting that this
protein may be a principle mediator in 1,25(OH)2D G1 cell cycle arrest15.
Another possible mechanism of dysregulation in cancer that affects cell cycle may be
signal transduction pathways. One of these pathways includes the MAP kinase which is a part of
signaling cascade pathway that regulates gene transcription16 important in cell cycle regulation
Recent studies have shown that Src, a non-receptor tyrosine kinase, becomes more
phosphorylated with the addition of 1,25(OH)2D, inhibiting its kinase activity. This results in
downstream MAPK (ERK-1 and ERK-2 MAP kinases) to be repressed16, suggesting that
1,25(OH)2D may also regulate cell cycle through the Src/MAP kinase signaling pathway.
Previous findings from our lab have shown an association between 1,25(OH)2D treatment
with decreased viable cell number, induction of cell apoptosis, and cell cycle regulation by
inducing G1/G0 cell cycle arrest. These results were modeled using MFC10A cells transfected
with the Harvey ras oncogene (MCF10A-ras). This inhibition of cell cycle proliferation could
contribute to the decrease in viable cell number via 1,25(OH)2D and therefore preventing breast
cancer progression. The purpose of this study is to investigate the role of 1,25(OH)2D in cell
cycle regulation and G1/G0 arrest in additional human breast epithelial cells in progression to
cancer. Therefore, it is hypothesized that the addition of 1,25(OH)2D to the four cell lines used
will induce G1/G0 cell cycle arrest by increasing the proportion of cells found in G1/G0 phase.

To study cancer progression and prevention, it is important to use appropriate models.
The most commonly used and appropriate model for studying breast cancer progression are the
MCF10A series (MCF10A, MCF10A-Ras, MCF10A-ErbB2, and MCF10CA1). MCF10A cells
were derived from benign breast tissue that spontaneously immortalized and are proposedly the
most common cell line used to model breast cells17. These cells have proliferative properties, but
do not express the estrogen receptor. They contain a deletion in the locus that contains genes
important for regulation of senescence and overexpression of the Myc gene. However, the
MCF10A cells express a basal-like phenotype, yet express some features resembling
mesenchymal cancer cells. This cell line led to the establishment of a series of cell lines
including more aggressive breast cancer lines17. The MCF10A-Ras cell line serves as a model for
the Harvey-Ras (Ha-Ras) proto-oncogenic effector utilized for growth-dependent induction of
several growth factors and cytokines18. Ha-Ras induced tumors contain activated mitogenactivated protein kinase (MAPK) signaling cascades. Ras activation is also involved in
overexpression of ErbB2 in breast tumors. Mutations in Ras are rare in breast cancers, but Ras is
improperly activated in about 50% of breast tumors and is associated with early neoplasia and
poor prognosis18.
The MCF10A-ErbB2 cell line contains a transformed ErbB2 gene. ErbB2 is an
oncoprotein in the family of epidermal growth factor receptors (EFG) of receptor tyrosine
kinases20. However, ErbB2 does not directly bind growth factors because it does not contain a
ligand binding domain. Instead, it forms a heterodimer with other EFG receptors that are bound
to ligands. This interaction leads to increased ligand binding and increased kinase-mediated
activation of downstream signaling pathways. Overexpression and amplification of ErbB2 is
found in cancers20, including about 1 in 4 cases of invasive breast cancer21. The overexpression

of ErbB2 has also been shown to initiate breast cancer invasion and metastasis, leading to poor
patient survival. The MCF10CA1a cell line is a metastatic line derived from the MCF10A-Ras
cells22. These cells are oncogenic, fully malignant, and are histologically undifferentiated,
morphologically variable, and anchorage-independent23. The MCF10CA1a cell line serves as a
valuable model for analyzing the oncogenic potential of genes of interest22
There is evidence that a higher vitamin D status is associated with a decreased risk of
metastasis, but the mechanistic basis for this is still under investigation. In numerous studies,
1,25(OH)2D has been shown to inhibit cell differentiation, apoptosis promotion, cell
proliferation, and cell cycle arrest in breast cancer cells. Cell proliferation is normally controlled
by the cell cycle, which is composed of a series of events that control the replication of the
genetic material and division of the cell. The cell cycle process is tightly controlled and divided
into phases. In breast cancer cells, normal regulation of the cell cycle is typically altered in order
to promote increased cell proliferation. Therefore, the regulation of the cell cycle is considered to
be a potential target for cancer therapy. Previous research in our lab demonstrated that MCF10Aras cells treated with 1,25(OH)2D induced G1 cell cycle arrest. These results led to the interest in
further investigating the effects of 1,25(OH)2D in human breast epithelial cells during cancer
progression.

Purpose
The purpose of this study is to investigate the role of 1,25(OH)2D in cell cycle regulation and
G1/G0 arrest in human breast epithelial cells in progression to cancer.

Study Design & Methods
Cell Lines
The cell lines used for experiments were MCF10A, MCF10A-ras, MCF10A-ErbB2, and
MCF10CA1a. MCF10A cells are benign human breast epithelial cells17. MCF10A-Ras are
Harvey-Ras oncogene transfected MCF10A cells18. MCF10A-ErbB2 are ErbB2/HER2/Neu
oncogene transfected MCF10A cells20. MCF10CA1a cells are tumorigenic derivative from
MCF10A-ras cells22.

Cell Culture
Cells were grown and maintained in culture Dulbecco’s Modified Eagle Medium/F12
(DMEM/F12) (1:1) nutrient mix containing 5% horse serum, 1% penicillin/streptomycin (Life
Technologies, Gibco-BRL, Rockville, MD). For MCF10A, MCF10A-ErbB2, and MC10A-Ras:
10mg/L insulin, 20ug/L epidermal growth factor, 50mg/L hydrocortisone (Sigma-Aldrich, St.
Louis, MO), and 50ug/L cholera toxin (Calbiochem, Darmstadt, Germany) were supplemented to
the media. Cells were plated at 300,000 cells per 60mm culture dish and allowed to attach
overnight. Then 10nM 1,25(OH)2D (Biomol, Plymouth Meeting, PA) treatment was delivered to
cells in 100% ethanol at a final ethanol concentration of <1% for 72 hours. Media supplemented
with 1,25(OH)2D was replaced every 24 hours during the treatment period. Plates were kept in a
humidified environment at 37 C.

Cell Cycle Measurement

Flow cytometry was used for cell cycle measurements. From each sample, 1x106 cells

were harvested using phosphate buffered saline in a single cell suspension. Cells were fixed with
ice cold ethanol then pretreated with 0.2 mg/mL Rnase A, and stained with 10 ug/mL propidium
iodide (Sigma-Aldrich, St. Louis, MO). Cell cycle quantifications were achieved using flow
cytometry analysis with a Beckman Coulter FC500 flow cytometer equipped with a 488 nm
laser. The results were analyzed with FloJo (Tree Star, Inc., Ashland, OR). Results were
expressed as percentage of total cells arrested in each phase in the cell cycle.

Figure 2. Cytomics FC 500 Flow Cytometer. Cells were stained with propidium iodide (PI)
which binds to double stranded DNA by intercalating between base pairs. The flow cytometer
emits a laser light that passes through one cell at a time. A detection apparatus absorbs the
refracted light at FL3 (670LP, red). The fluorescence intensity is proportional to the DNA
concentration within the cell and this is indicative of its cell cycle phase15.

Statistical Analysis
Results were compared using the Student’s t-test including the means +/- SD. P-values <

0.05 are considered significant.

Results
Impact of 1,25(OH)2D on cell cycle regulation in MCF10A, MFC10A-Ras, MCF10A-ErbB2, and
MCF10CA1a cels.
In order to determine if 1,25(OH)2D regulates the cell cycle in breast epithelial cells,
analysis of cell cycle phases was determined in MCF10A, MFC10A-Ras, MCF10A-ErbB2, and
MCF10CA1a cells. In MCF10A cells, the addition of 1,25(OH)2D (10 nM) significantly
increased the number of cells arrested in the G1/G0 phase (p=0.03). Treatment with 1,25(OH)2D
did not significantly change the number of cells in G2 relative to the vehicle (p=0.21).
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Figure 3. 1,25(OH)2D Regulation of MCF10A Cell Cycle. Cells were treated
with either vehicle or 10 nM 1,25(OH)2D for 72 hours, and harvested for cell

cycle analysis and quantification by flow cytometry. Bars with asterisks(*)
indicate significance (p < 0.05) by Student’s t-test including the means +/- SD.

In MCF10A-Ras cells, the addition of 1,25(OH)2D (10 nM) significantly increased the
number of cells arrested in the G1/G0 phase (p=0.002). The number of cells in G2 significantly
decreased relative to the vehicle with 1,25(OH)2D treatment (p=0.0006).
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Figure 4. 1,25(OH)2D Regulation of MCF10A-Ras Cell Cycle. Cells were
treated with either vehicle or 10 nM 1,25(OH)2D for 72 hours, and harvested for
cell cycle analysis and quantification by flow cytometry. Bars with asterisks(*)
indicate significance (p < 0.05) by Student’s t-test including the means +/- SD.

In MCF10A-ErbB2 cells, the addition of 1,25(OH)2D (10 nM) significantly increased the
number of cells arrested in the G1/G0 phase (p=0.01). With 1,25(OH)2D treatment, the number
of cells in G2 did not show a significant change relative to the vehicle (p=0.83).
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Figure 5. 1,25(OH)2D Regulation of MCF10A-ErbB2 Cell Cycle. Cells were
treated with either vehicle or 10nM 1,25(OH)2D for 72 hours, and harvested for
cell cycle analysis and quantification by flow cytometry. Bars with asterisks(*)
indicate significance (p < 0.05) by Student’s t-test including the means +/- SD.

In MCF10CA1a cells, the addition of 1,25(OH)2D (10 nM) significantly increased the
number of cells arrested in the G1/G0 phase (p=0.00005). The number of cells in G2 did not
significantly change relative to the vehicle with 1,25(OH)2D treatement (p=0.23).
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Figure 6. 1,25(OH)2D Regulation of MCF10CA1a Cell Cycle. Cells were
treated with either vehicle or 10nM 1,25(OH)2D for 72 hours, and harvested for
cell cycle analysis and quantification by flow cytometry. Bars with asterisks(*)
indicate significance (p < 0.05) by Student’s t-test including the means +/- SD.

Discussion
There is evidence that higher vitamin D status is associated with a decreased risk of
metastasis, but the mechanistic basis has not been determined. In numerous studies, 1,25(OH)2D
has been shown to inhibit cell proliferation, cell cycle arrest, cell differentiation, and promote

apoptosis in breast cancer cells. Previous studies in our lab have shown that 1,25(OH)2D arrests
cells in the cell cycle and induces apoptosis in MCF10A and MCF10A-Ras cell lines. In the
current study, it is demonstrated that 1,25(OH)2D regulates the cell cycle by increasing the
percentage of cells arrested in the G1/G0 phase of the cell cycle. All four cell lines modeled for
breast cancer progression showed significant increases when treated for 72 hours: MCF10A
(P=0.03), MCF10A-ras (P=0.002), MCF10A-ErbB2 (P=0.01), and MCF10CA1a (P= 0.00005).
The results from this study are consistent with previous results from our lab using
MCF10A and MCF10A-Ras cells in which 1,25(OH)2D arrested cells in the G1/G0 phase of the
cell cycle. This study re-analyzed the MCF10A and MCF10A-Ras cells as well as two other cell
lines, MCF10A-ErbB2 and MCF10CA1a and the increased number of cells arrest in the G1/G0
phase further supports the hypothesis and previous findings.
There have been several possible mechanisms proposed to demonstrate the role of
vitamin D on the regulation of the cell cycle. Studies have shown that 1,25(OH)2D plays a role in
the expression of specific cell cycle regulators such as cyclin-dependent kinase inhibitors
(CDI’s). In particular the addition of 1,25(OH)2D to the CDI, p27Kip1, inhibits cell cycle
progression at the G1 phase through the interactions with CDK2 and CDK415. Another proposed
mechanism of 1,25(OH)2D regulation is via signal transduction pathways such as Src and the
MAP kinase cascade which regulate gene transcription . An upstream regulator of MAP kinase,
Src, may be inhibited by phosphorylation due to the addition of 1,25(OH)2D, resulting in
downstream repression of MAPK16. There is evidence that 1,25(OH)2D regulates various
pathways in gene transcription and cell cycle regulation that may lead to the arrest in G1/G0
phase and therefore reduction in cell proliferation and apoptosis.

These results indicate that 1,25(OH)2D is associated with regulating the cell cycle,
although the exact mechanism is still under consideration. Inhibition of the cell cycle may
explain the mechanism of vitamin D to inhibit breast cancer progression. Vitamin D may be an
essential molecule for inhibiting cell growth and proliferation which may contribute to its role in
breast cancer progression.
Understandings on the mechanisms by which vitamin D inhibits breast cancer
development and metastasis is important in order to design clinical trials to test the effect in
humans. Thus, the information from this study will potentially contribute to developing
recommendations for vitamin D intake that will prevent breast cancer development and
metastasis.

Conclusion
In MCF10A, MCF10A-Ras, MFC10A-ErbB2, and MCF10CA1a breast epithelial cell
lines, 1,25(OH)2D treatment for 72 hours increased the percent of cells arrested in G1/G0 phase
of the cell cycle. This indicates that these cells may be inhibited from progressing through the
cell cycle due to arrest in the G1/G0 phase. Therefore, inhibition of the cell cycle may explain
the effect of vitamin D to inhibit breast cancer progression. These results support the evidence
that vitamin D may be a factor in breast cancer prevention and inhibitor for proliferation.
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